PharmaPoint Prophylactic Human Papillomavirus Vaccines – Australia Drug Market Forecast and Analysis to 2022

The Report PharmaPoint: Prophylactic Human Papillomavirus Vaccines – Australia Drug Forecast and Market Analysis to 2022 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The Global HPV Vaccines Market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Mercks Gardasil, with GlaxoSmithKlines (GSKs) HPV vaccine Cervarix providing the only competition. The introduction of Mercks nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

GlobalData expects HPV vaccine coverage rates in Australia to remain relatively high throughout the forecast period, driven by a successful school-based immunization program. The inclusion of males in the school immunization program from 2013 will drive the expansion of the HPV vaccines market over the forecast period. GlobalData expects that following approval Mercks nine-valent vaccine V503 will be quickly adopted into the Australian school-based immunization program, and this will provide an additional boost to HPV vaccine sales in Australia.

Download Sample copy of this Report at :


Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on the key drugs in the Australia including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for the top drugs in the Australia from 2012-2022.

– Analysis of the impact of key events as well the drivers and restraints affecting the Australia Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of drug performance

– Obtain sales forecast for drugs from 2012-2022 in the Australia

Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 13

3.2 Symptoms 15

4 Vaccination Recommendations and Coverage Rates 17

4.1 Australia 17

4.1.1 Vaccination Recommendations and Policies 17

4.1.2 Vaccination Coverage 17

4.1.3 Clinical Practice 19

5 Competitive Assessment 20

5.1 Overview 20

5.2 Strategic Competitor Assessment 20

5.3 Product Profiles 22

5.3.1 Gardasil 22

5.3.2 Cervarix 28

6 Unmet Need and Opportunity 33

6.1 Overview 33

6.2 Protection against Multiple HPV Types 34

6.2.1 Unmet Need 34

6.2.2 Gap Analysis 35

6.2.3 Opportunity 36

6.3 Vaccine Coverage Rates 36

6.3.1 Unmet Need 36

6.3.2 Gap Analysis 37

6.3.3 Opportunity 37

6.4 Perception of Vaccine Safety 38

6.4.1 Unmet Need 38

6.4.2 Gap Analysis 39

6.4.3 Opportunity 39

6.5 Awareness of HPV Vaccination 40

6.5.1 Unmet Need 40

6.5.2 Gap Analysis 40

6.5.3 Opportunity 41

6.6 Affordability of HPV Vaccines 41

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074